Trials / Completed
CompletedNCT00992160
Vestipitant 28-day Tolerance Study
A 28-Day, Polysomnographic and Subjective Assessment of Vestipitant (15mg/Day) for the Treatment of Primary Insomnia in Adult Outpatients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 161 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
This study is a 28-day polysomnographic and subjective assessment of oral Vestipitant 15mg/day for treatment of Primary Insomnia in adults outpatients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW597599 | GW597599 15mg tablet |
| DRUG | Placebo | Placebo to match GW597599 15mg tablet |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2009-10-09
- Last updated
- 2016-10-28
Locations
13 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00992160. Inclusion in this directory is not an endorsement.